Results 251 to 260 of about 280,908 (318)

Prevalence and screening of interstitial lung disease in rheumatoid arthritis. [PDF]

Rheumatol Adv Pract
Gono T.
europepmc   +1 more source

Clinical Images: Subcutaneous panniculitis‐like T cell lymphoma

Arthritis &Rheumatology, EarlyView.
S Chambers, CN Myrdal, VP Werth
wiley   +1 more source

Treatment of a Large Cohort of Childhood Chronic Noninfectious Uveitis in a Multicentric Large Study: Adalimumab Versus Methotrexate as First‐Line Therapy

Arthritis &Rheumatology, EarlyView.
Objective Treatment of childhood chronic idiopathic uveitis (cCIU) is predominantly based on studies in juvenile idiopathic arthritis–associated uveitis and expert opinion. Our aim was to report the treatment outcomes of our cohort of cCIU. Methods Retrospective multicenter study involving the rheumatology and ophthalmology units at Florence, Italy ...
Ilaria Maccora, Catherine Guly, Cinzia de Libero, Giulia Carreras, Athimalaipet V. Ramanan, Gabriele Simonini   +5 more
wiley   +1 more source

Malignancy rates in children, young people and adults with JIA: an observational study using CPRD Aurum. [PDF]

Rheumatology (Oxford)
Kearsley-Fleet L, Merriel SWD, Shaw N, Leslie J, Johnson M, Wedderburn LR, Wedderburn LR, Hyrich KL, Humphreys JH.   +8 more
europepmc   +1 more source

Multimodal Integration of Protein Interactomes With Genomic and Molecular Data Discovers Distinct Rheumatoid Arthritis Endotypes

Arthritis &Rheumatology, EarlyView.
Objective Rheumatoid arthritis (RA) is a heterogeneous autoimmune disease characterized by clinical and molecular heterogeneity, notably in the presence of anti–cyclic citrullinated peptide (CCP) antibodies. Patients with CCP+ RA exhibit more severe disease progression and distinct treatment responses compared to patients with CCP− RA.
Javad Rahimikollu, Priyamvada Guha Roy, Akash Kishore, Danica Morgan Lee, Lauren A. Vanderlinden, Kiran Nazarali, Fan Zhang, Dana P. Ascherman, Daniella M. Schwartz, Larry Moreland, Jishnu Das   +10 more
wiley   +1 more source

Cross-national biologic treatment guidelines for FMF: a comparative analysis. [PDF]

Rheumatology (Oxford)
Kasap Cuceoglu M, Hinze T, Wittkowski H, Haslak F, Mamutova A, Oner N, Caorsi R, Bourguiba R, Elhani I, Delplanque M, El Moussaoui M, Pateras K, Sestan M, Kirijas M, Constantin T, Ducharme-Benard S, Lanchmann H, Butbul Aviel Y, Hentgen V.   +18 more
europepmc   +1 more source

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study

Arthritis &Rheumatology, EarlyView.
Objective To evaluate the efficacy and safety of guselkumab, an interleukin‐23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor.
Alexis Ogdie, Joseph F. Merola, Philip J. Mease, Christopher T. Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D. Chakravarty, Wayne Langholff, Yanli Wang, Jie Shao, Yevgeniy Krol, Alice B. Gottlieb   +12 more
wiley   +1 more source

Multicentre cohort study on the course of paediatric familial Mediterranean fever in the aftermath of the 2023 earthquake. [PDF]

BMJ Paediatr Open
Cam V, Yalcin SS, Batu ED, Kacmaz HM, Kocamaz NG, Günal Ö, Kayhan E, Bozkaya B, Taşkın S, Gungorer V, Kılıç Konte E, Pirim G, Ünal D, Ozdel S, Koker O, Pac Kısaarslan A, Kisla Ekinci RM, Dogantan Ş, Demir S, Ozturk K, Adıgüzel Dundar H, Basaran O, Balat A, Sozeri B, Kasapcopur O, Bilginer Y, Ozen S.   +26 more
europepmc   +1 more source

A Metabolomic Signature Predicts Gout Flare Clinical Outcome Associated With Colchicine Prophylaxis

Arthritis &Rheumatology, EarlyView.
Objective This study investigated that serum metabolomics, before urate‐lowering therapy (ULT) initiation, could serve as a biomarker for responsiveness to colchicine prophylaxis in patients with gout commencing treat‐to‐target ULT. Methods We studied a multicenter prospective cohort (n = 409) initiating treat‐to‐target ULT plus colchicine prophylaxis.
Wenyan Sun, Lingfang Xu, Haibing Chen, Mingshu Sun, Zhiqiang Li, Rui Li, Lidan Ma, Hui Zhang, Aichang Ji, Yuwei He, Na Wu, Le Yan, Robert Terkeltaub, Changgui Li   +13 more
wiley   +1 more source